If you have hypertrophic cardiomyopathy (HCM) and are experiencing symptoms such as shortness of breath, chest pain, ...
Learn the key differences between obstructive and nonobstructive HCM, including how your specific diagnosis can impact ...
SOUTH SAN FRANCISCO, Calif., Aug. 21, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced that it has dosed the first subjects in a Phase 1 clinical study of MYK-224, a small ...
The heart's ability to beat normally over a lifetime is predicated on the synchronized work of proteins embedded in the cells of the heart muscle. Like a fleet of molecular motors that get turned on ...
Hypertrophic cardiomyopathy (HCM) is the most common of all genetic heart diseases and is the leading cause of sudden cardiac death. It is characterized by an abnormal thickening of the heart muscle, ...
EXPLORER-HCM Cardiac Imaging Data Presented at AHA 2020 Scientific Session with Simultaneous Publication in Circulation Mavacamten Treatment Resulted in Favorable Effect on Cardiac Structure -- ...
BRISBANE, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to ...